Advances in Drug Delivery in Cancer Treatment
A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Nanobiotechnology and Biofabrication".
Deadline for manuscript submissions: 30 September 2025 | Viewed by 631
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer is a complex and challenging disease that continues to be a major health concern worldwide. Recent advances in drug delivery systems have shown promise in improving the efficacy and safety of cancer treatment. The development of targeted drug delivery systems has allowed for the more precise delivery of anti-cancer drugs to tumor sites, reducing off-target effects and minimizing toxicity. Nanotechnology-based drug delivery systems, such as nanoparticles and liposomes, have enabled enhanced drug delivery across biological barriers and improved drug stability, bioavailability, and pharmacokinetics. Additionally, the use of combination therapies, including drug-loaded nanoparticles and immunotherapy, has shown synergistic effects in enhancing anti-cancer activity and overcoming drug resistance.
This Special Issue aims to highlight the latest research and developments in drug delivery for cancer treatment. It will feature original research articles, reviews, and perspectives that cover a wide range of topics, including novel drug delivery systems, targeting strategies, biomaterials, and clinical translation of drug delivery technologies. By bringing together researchers and experts in the field, this Special Issue will provide valuable insights into the current challenges and opportunities in drug delivery for cancer therapy.
Dr. Chang Yang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- drug delivery
- nanotechnology
- targeted therapy
- combination therapy
- biomaterials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
